Heger Jan-Michel, Borchmann Peter, Riou Sybille, Werner Barbara, Papadimitrious Michael S, Mahlich Jörg
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany.
Health Economics and Outcomes Research, Miltenyi Biomedicine, Bergisch Gladbach, Germany.
Front Oncol. 2024 Oct 9;14:1432310. doi: 10.3389/fonc.2024.1432310. eCollection 2024.
Limited real-world evidence is available for patients with diffuse large B-cell lymphoma (DLBCL) who received an autologous stem cell transplantation (ASCT) in Germany.
This study aims to describe the real-world survival outcomes of patients with DLBCL who received ASCT in Germany after diagnosis.
This study is a retrospective database analysis covering the period between 2010 and 2019.
Unadjusted overall survival (OS) was plotted using the Kaplan-Meier estimator for the overall population and stratified by relapse status. A Cox regression was run to identify factors that influence OS.
A total of 112 patients received an ASCT, with the average time from first-line treatment to ASCT being 11.7 months. The median OS estimated by Kaplan-Meier was 83.4 months for the entire cohort. The only variable that significantly reduced the OS was the presence of subsequent treatment after ASCT in a time-dependent model.
OS after ASCT for DLBCL patients in Germany is higher than previously reported and may still be considered a valid option for carefully selected patients with relapsed/refractory DLBCL.
在德国，接受自体干细胞移植（ASCT）的弥漫性大B细胞淋巴瘤（DLBCL）患者的真实世界证据有限。
本研究旨在描述德国诊断后接受ASCT的DLBCL患者的真实世界生存结局。
本研究是一项回顾性数据库分析，涵盖2010年至2019年期间。
使用Kaplan-Meier估计器绘制总体人群的未调整总生存期（OS），并按复发状态分层。进行Cox回归以确定影响OS的因素。
共有112例患者接受了ASCT，从一线治疗到ASCT的平均时间为11.7个月。整个队列通过Kaplan-Meier估计的中位OS为83.4个月。在时间依赖性模型中，唯一显著降低OS的变量是ASCT后进行后续治疗。
德国DLBCL患者ASCT后的OS高于先前报道，对于精心挑选的复发/难治性DLBCL患者，仍可被视为一种有效的选择。
